Q&A: Covid-19’s Delta subvariant and the risky winter ahead
Virologist Dr Phillip Gould discusses the Delta subvariant, vaccines, and the new Covid-19 antiviral molnupiravir.
By
Respiratory
Latest in
Respiratory
UK grants world-first approval to Covid-19 pill molnupiravir
Molnupiravir is the first oral antiviral medication to be approved for the treatment of Covid-19.
By
Molnupiravir: long-term safety questions linger as approvals approach
Some experts have concerns about the safety of Merck’s investigational Covid-19 antiviral molnupiravir.
By
Covis Pharma to acquire AstraZeneca’s medicines for $270m
The inhaled respiratory treatments are intended to treat chronic obstructive pulmonary disease.
Will Merck’s Covid-19 pill be available to lower-income countries?
Approval of Merck’s molnupiravir would be an important step towards tackling Covid-19 – but will those in poorer countries be…
By
BCG: the history and modern-day uses of the tuberculosis vaccine
With the BCG jab showing promise against Covid-19, we profile the history of the TB vaccine and its diverse applications…
By
4D Pharma Q&A: the potential of gut bacteria in cancer and beyond
4D Pharma CEO Duncan Peyton discusses the company’s work on bacteria-based therapies for cancer, neurodegeneration and more.
By
Drugmakers are racing to develop an antiviral pill for Covid-19
With vaccination campaigns rolling out, pharma companies are competing to get Covid-19 antiviral drugs approved and on the market.
By